ClinicalTrials.gg
CompletedNCT04987320Updated Feb 10, 2025Results posted

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

A Phase 1 interventional study of Olpasiran in Elevated Serum Lipoprotein(a), sponsored by Amgen. Completed at 1 site in Hong Kong. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The main objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of Olpasiran in Chinese participants with elevated serum lipoprotein(a) (Lp[a]).

02

Conditions studied

  • Elevated Serum Lipoprotein(a)

Keywords

  • Elevated serum lipoprotein(a)
  • Olpasiran
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion eligibility criteria will be evaluated in 2 parts during the screening period:

  • Part 1: After written is obtained, subjects will provide a blood sample for a preliminary Lp(a) assessment to determine eligibility for Part 2 screening. Subjects with Lp(a) ≥ 70 nmol/L (or approximately ≥ 27 mg/dL) will be eligible to return to the CRU Part 2 screening. Subjects not eligible to return for Part 2 screening will be screen failed.
  • Part 2: Eligible subjects will complete all remaining screening procedures and tests that establish eligibility within 40 days prior to the Day 1 visit.

Part 1:

  • Must be a resident in mainland China, Hong Kong, or Taiwan, and of Chinese Ancestry.
  • Male or female subjects, between 18 and 60 years of age (inclusive) at the time of Screening.
  • Screening serum Lp(a) ≥ 70 nmol/L (or approximately ≥ 27 mg/dL).

Part 2:

  • In good health, determined by no findings from medical history, physical examination, 12-lead , vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) as assessed by the Investigator (or designee).
  • between 18 and 32 kg/m\^2 (inclusive) at the time of Screening.
  • Subjects who are on statin must be on a stable dose of the same statin for at least 6 weeks prior to enrollment, and plan to remain on a stable dose (i.e., no change in medication or dosage) for the duration of the study.
  • Females must be of non-:

    a. defined as: i. Age of ≥ 55 years with no menses for at least 12 months; OR ii. Age of \< 55 years with no menses for at least 12 months AND with a follicle stimulating hormone (FSH) level > 40 IU/L or according to the definition of "postmenopausal range" for the laboratory involved; OR b. History of hysterectomy; OR c. History of bilateral oophorectomy.

Exclusion criteria

Exclusion Criteria:

  • History or clinical evidence of peripheral neuropathy.
  • Currently receiving apheresis as lipid reducing therapy.
  • History or clinical evidence of bleeding diathesis or any coagulation disorder, including (PT), activated partial thromboplastin time (APTT), or count outside of the laboratory's normal reference range at screening. Subjects with PT and/or APTT values that are outside of the laboratory's normal reference range at screening may still be eligible to proceed to enrollment if the results are judged by the investigator in consultation with the study medical monitor to not be .
  • History or clinical evidence of diabetes mellitus, including a fasting glucose ≥ 125 mg/dL (6.9 mmol/L) at Screening.
  • Use of any herbal medicines, vitamins or dietary supplements known to affect lipid metabolism (e.g. sigh oils > 100mg/day, red yeast extract), within 30 days prior to dosing on Day 1 and for the duration of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Olpasiran Dose A

    Participants will be administered Olpasiran dose A as a subcutaneous injection.

    Drug: Olpasiran

  • Experimental
    Olpasiran Dose B

    Participants will be administered Olpasiran dose B as a subcutaneous injection.

    Drug: Olpasiran

Interventions

  • Subcutaneous injection

    Also known as: AMG 890

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Olpasiran

    The serum pharmacokinetic (PK) parameters of olpasiran were calculated using standard noncompartmental methods.

    Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85

Secondary outcomes

  1. Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Olpasiran

    The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

    Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85

  2. Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Olpasiran

    The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

    Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85

  3. Time to Cmax (Tmax) of Olpasiran

    The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

    Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85

  4. Apparent Terminal Elimination Half-life (T1/2) of Olpasiran

    The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

    Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85

  5. Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Olpasiran

    The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

    Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85

  6. Apparent Total Body Clearance (CL/F) of Olpasiran

    The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

    Time frame: Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85

  7. Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as an AE that starts on or after the first dose of investigational product and up to end of study. Clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms, and vital signs were reported as AEs.

    Time frame: Up to Day 225

  8. Percentage Change From Baseline in Triglycerides

    Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

    Time frame: Baseline and Days 7, 15, 57, 155 and 225

  9. Percentage Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C)

    Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

    Time frame: Baseline and Days 7, 15, 57, 155 and 225

  10. Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

    Time frame: Baseline and Days 7, 15, 57, 155 and 225

  11. Percentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

    Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

    Time frame: Baseline and Days 7, 15, 57, 155 and 225

  12. Percentage Change From Baseline in Total Cholesterol

    Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

    Time frame: Baseline and Days 7, 15, 57, 155 and 225

  13. Percentage Change From Baseline in Apolipoprotein A1 (ApoA1)

    Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

    Time frame: Baseline and Days 7, 15, 57, 155 and 225

  14. Percentage Change From Baseline in Apolipoprotein B (Apo B)

    Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

    Time frame: Baseline and Days 7, 15, 57, 155 and 225

  15. Percentage Change From Baseline in Lipoprotein-a (Lp[a])

    Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

    Time frame: Baseline and Days 2, 4, 7, 15, 29, 57, 85, 113, 155, 183 and 225

07

Results

Posted Feb 10, 2025

Participant flow

Participant flow — Overall Study
MilestoneOlpasiran Low DoseOlpasiran High Dose
Started1212
Completed1211
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of Olpasiran

The serum pharmacokinetic (PK) parameters of olpasiran were calculated using standard noncompartmental methods.

Time frame:
Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of Olpasiran
ng/mLOlpasiran Low DoseOlpasiran High Dose
Maximum Observed Concentration (Cmax) of Olpasiran144 ± 55.5549 ± 71.5
SecondaryArea Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Olpasiran

The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

Time frame:
Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Reported as:
Geometric mean · h*ng/mL
Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Olpasiran
h*ng/mLOlpasiran Low DoseOlpasiran High Dose
Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Olpasiran2660 ± 24.012000 ± 41.2
SecondaryArea Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Olpasiran

The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

Time frame:
Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Reported as:
Geometric mean · h*ng/mL
Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Olpasiran
h*ng/mLOlpasiran Low DoseOlpasiran High Dose
Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Olpasiran2660 ± 24.212000 ± 41.3
SecondaryTime to Cmax (Tmax) of Olpasiran

The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

Time frame:
Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Reported as:
Median · hours
Time to Cmax (Tmax) of Olpasiran
hoursOlpasiran Low DoseOlpasiran High Dose
Time to Cmax (Tmax) of Olpasiran3.02 (2.85 to 9.00)3.11 (2.88 to 12.0)
SecondaryApparent Terminal Elimination Half-life (T1/2) of Olpasiran

The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

Time frame:
Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Reported as:
Mean · hours
Apparent Terminal Elimination Half-life (T1/2) of Olpasiran
hoursOlpasiran Low DoseOlpasiran High Dose
Apparent Terminal Elimination Half-life (T1/2) of Olpasiran6.05 ± 1.596.69 ± 1.58
SecondaryApparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Olpasiran

The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

Time frame:
Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Reported as:
Geometric mean · liters
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Olpasiran
litersOlpasiran Low DoseOlpasiran High Dose
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Olpasiran238 ± 43.5176 ± 60.2
SecondaryApparent Total Body Clearance (CL/F) of Olpasiran

The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.

Time frame:
Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Reported as:
Geometric mean · L/h
Apparent Total Body Clearance (CL/F) of Olpasiran
L/hOlpasiran Low DoseOlpasiran High Dose
Apparent Total Body Clearance (CL/F) of Olpasiran28.2 ± 24.018.8 ± 41.2
SecondaryNumber of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as an AE that starts on or after the first dose of investigational product and up to end of study. Clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms, and vital signs were reported as AEs.

Time frame:
Up to Day 225
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
ParticipantsOlpasiran Low DoseOlpasiran High Dose
Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)1210
SecondaryPercentage Change From Baseline in Triglycerides

Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

Time frame:
Baseline and Days 7, 15, 57, 155 and 225
Reported as:
Mean · percentage change in triglycerides
Percentage Change From Baseline in Triglycerides
percentage change in triglyceridesOlpasiran Low DoseOlpasiran High Dose
Day 721.8 ± 30.1-10.0 ± 39.1
Day 1510.4 ± 33.2-12.9 ± 22.1
Day 577.55 ± 35.1-2.35 ± 36.3
Day 155-2.87 ± 32.8-16.2 ± 25.3
Follow-up (Day 225)26.6 ± 50.7-10.4 ± 23.7
SecondaryPercentage Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C)

Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

Time frame:
Baseline and Days 7, 15, 57, 155 and 225
Reported as:
Mean · percentage change in VLDL-C
Percentage Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C)
percentage change in VLDL-COlpasiran Low DoseOlpasiran High Dose
Day 723.5 ± 37.7-8.43 ± 40.2
Day 1513.5 ± 41.8-8.10 ± 32.3
Day 577.94 ± 38.34.55 ± 60.4
Day 155-0.165 ± 43.1-11.9 ± 39.0
Follow-up (Day 225)26.7 ± 48.4-7.58 ± 28.1
SecondaryPercentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

Time frame:
Baseline and Days 7, 15, 57, 155 and 225
Reported as:
Mean · percentage change in LDL-C
Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
percentage change in LDL-COlpasiran Low DoseOlpasiran High Dose
Day 7-4.17 ± 13.11.22 ± 8.36
Day 15-0.843 ± 14.33.97 ± 11.9
Day 570.201 ± 9.642.29 ± 9.73
Day 155-5.91 ± 13.5-3.82 ± 12.6
Follow-up (Day 225)2.01 ± 17.7-5.55 ± 10.9
SecondaryPercentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

Time frame:
Baseline and Days 7, 15, 57, 155 and 225
Reported as:
Mean · percentage change in HDL-C
Percentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
percentage change in HDL-COlpasiran Low DoseOlpasiran High Dose
Day 73.80 ± 7.287.41 ± 6.57
Day 156.65 ± 6.1811.0 ± 5.97
Day 577.17 ± 10.81.29 ± 8.40
Day 15521.8 ± 11.021.3 ± 9.82
Follow-up (Day 225)13.9 ± 5.2511.3 ± 15.3
SecondaryPercentage Change From Baseline in Total Cholesterol

Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

Time frame:
Baseline and Days 7, 15, 57, 155 and 225
Reported as:
Mean · percentage change in total cholesterol
Percentage Change From Baseline in Total Cholesterol
percentage change in total cholesterolOlpasiran Low DoseOlpasiran High Dose
Day 70.923 ± 10.20.956 ± 6.78
Day 152.45 ± 9.523.70 ± 9.03
Day 572.17 ± 7.410.879 ± 7.20
Day 1551.20 ± 9.710.689 ± 8.03
Follow-up (Day 225)6.95 ± 9.43-1.82 ± 8.33
SecondaryPercentage Change From Baseline in Apolipoprotein A1 (ApoA1)

Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

Time frame:
Baseline and Days 7, 15, 57, 155 and 225
Reported as:
Mean · percentage change in ApoA1
Percentage Change From Baseline in Apolipoprotein A1 (ApoA1)
percentage change in ApoA1Olpasiran Low DoseOlpasiran High Dose
Day 72.86 ± 9.633.75 ± 9.46
Day 158.10 ± 5.617.95 ± 8.65
Day 570.185 ± 8.20-0.294 ± 8.32
Day 15511.4 ± 9.469.31 ± 9.47
Follow-up (Day 225)18.1 ± 8.2711.7 ± 14.0
SecondaryPercentage Change From Baseline in Apolipoprotein B (Apo B)

Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

Time frame:
Baseline and Days 7, 15, 57, 155 and 225
Reported as:
Mean · percentage change in Apo B
Percentage Change From Baseline in Apolipoprotein B (Apo B)
percentage change in Apo BOlpasiran Low DoseOlpasiran High Dose
Day 70.0576 ± 11.11.41 ± 7.54
Day 152.65 ± 8.991.77 ± 9.34
Day 573.66 ± 10.01.59 ± 8.49
Day 155-0.834 ± 12.9-0.958 ± 9.01
Follow-up (Day 225)5.64 ± 12.4-1.90 ± 11.5
SecondaryPercentage Change From Baseline in Lipoprotein-a (Lp[a])

Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.

Time frame:
Baseline and Days 2, 4, 7, 15, 29, 57, 85, 113, 155, 183 and 225
Reported as:
Mean · percentage change in Lp(a)
Percentage Change From Baseline in Lipoprotein-a (Lp[a])
percentage change in Lp(a)Olpasiran Low DoseOlpasiran High Dose
Day 20.245 ± 8.57-0.295 ± 9.84
Day 4-4.93 ± 11.4-17.6 ± 12.6
Day 7-32.9 ± 13.2-49.8 ± 16.3
Day 15-77.3 ± 8.46-84.2 ± 10.7
Day 29-91.0 ± 4.20-95.2 ± 5.50
Day 57-94.8 ± 3.80-99.2 ± 1.65
Day 85-91.4 ± 9.89-98.9 ± 1.84
Day 113-87.8 ± 11.1-97.7 ± 2.84
Day 155-75.8 ± 17.9-93.7 ± 5.13
Day 183-67.3 ± 18.0-89.1 ± 8.17
Follow-up (Day 225)-55.1 ± 18.5-81.5 ± 11.8

Adverse events

Collected over Up to 225 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olpasiran Low Dose0/12 (0%)1/12 (8.3%)11/12 (91.7%)
Olpasiran High Dose0/12 (0%)1/12 (8.3%)9/12 (75%)
Most frequent serious events
Most frequent serious events
EventOlpasiran Low DoseOlpasiran High Dose
Clavicle fractureInjury, poisoning and procedural complications1/120/12
Alanine aminotransferase increasedInvestigations0/121/12
Aspartate aminotransferase increasedInvestigations0/121/12
Most frequent other events
Showing 10 of 34
Most frequent other events
EventOlpasiran Low DoseOlpasiran High Dose
DiarrhoeaGastrointestinal disorders3/121/12
PyrexiaGeneral disorders3/120/12
Covid-19Infections and infestations1/123/12
Injection site erythemaGeneral disorders0/122/12
ContusionInjury, poisoning and procedural complications1/122/12
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/120/12
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/120/12
RashSkin and subcutaneous tissue disorders2/121/12
Abdominal discomfortGastrointestinal disorders0/121/12
GastritisGastrointestinal disorders1/120/12

Baseline characteristics

Safety Analysis Set: included all randomized participants who received olpasiran.

Age, Continuous
Age, Continuous(years)Olpasiran Low DoseOlpasiran High DoseTotal
Mean41.3 ± 11.2349.4 ± 9.2345.3 ± 10.88
Sex: Female, Male
Sex: Female, Male(Participants)Olpasiran Low DoseOlpasiran High DoseTotal
Female257
Male10717
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olpasiran Low DoseOlpasiran High DoseTotal
Hispanic or Latino000
Not Hispanic or Latino121224
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olpasiran Low DoseOlpasiran High DoseTotal
American Indian or Alaska Native000
Asian121224
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Queen Mary Hospital
    Hong Kong, HK, Hong Kong
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Nov 2021, 3 months.

Results were first posted in Feb 2025, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2021
First posted
Aug 3, 2021
StartActual
Jul 28, 2021
Primary completionActual
Nov 12, 2021
CompletionActual
Mar 18, 2022
Results first posted
Feb 10, 2025
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04987320
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 3, 2021
Start date
Jul 28, 2021
Primary completion
Nov 12, 2021
Completion
Mar 18, 2022
Results posted
Feb 10, 2025
Last update
Feb 10, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olpasiran

Start the discussion